Zymeworks (NASDAQ:ZYME) Rating Increased to Strong-Buy at Citizens Jmp

Citizens Jmp upgraded shares of Zymeworks (NASDAQ:ZYME) to a strong-buy rating in a report issued on Wednesday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on ZYME. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research note on Wednesday, October 8th. B. Riley upgraded shares of Zymeworks to a “strong-buy” rating in a research note on Thursday, October 9th. Zacks Research lowered shares of Zymeworks from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. HC Wainwright upgraded shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, Wells Fargo & Company raised shares of Zymeworks to a “hold” rating in a report on Friday, October 24th. Three equities research analysts have rated the stock with a Strong Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Zymeworks Price Performance

Shares of ZYME stock opened at $26.52 on Wednesday. The company has a market cap of $1.98 billion, a P/E ratio of -31.57 and a beta of 1.27. The stock has a 50-day moving average of $20.00. Zymeworks has a one year low of $9.03 and a one year high of $28.49.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $27.61 million for the quarter, compared to analysts’ expectations of $28.27 million. Zymeworks had a negative return on equity of 19.25% and a negative net margin of 47.16%.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.